Group 1 - The core viewpoint of the article highlights that Sihuan Pharmaceutical (00460) has seen a significant stock price increase, attributed to its strategic partnership with Deep Origin Pharmaceutical to establish an AI-driven R&D company focused on medical beauty products [1] - Sihuan Pharmaceutical's mid-term performance report indicates a revenue of 1.146 billion RMB, representing a year-on-year increase of 20.69%, and a net profit attributable to shareholders of 103 million RMB, marking a turnaround from losses [1] - The company plans to distribute an interim cash dividend of 0.99 cents per share, reflecting its improved financial performance [1] Group 2 - The collaboration with Deep Origin Pharmaceutical signifies a substantial step in Sihuan Pharmaceutical's strategic layout in the "AI + Medical Beauty" innovation sector [1] - The company's medical beauty platform, Meiyan Space, has successfully enhanced strategic partnerships with various medical beauty institutions and implemented a marketing strategy 3.0 upgrade, leading to a significant increase in sales revenue [1] - The products developed under this initiative have received high market recognition, further driving the growth of the medical beauty segment [1]

Group 1 - The core viewpoint of the article highlights that Sihuan Pharmaceutical (00460) has seen a significant stock price increase, attributed to its strategic partnership with Deep Origin Pharmaceutical to develop AI-driven medical beauty products [1] - Sihuan Pharmaceutical's stock rose over 7% during trading, with a current increase of 4.11%, reaching HKD 1.52, and a trading volume of HKD 168 million [1] - The company reported a 20.69% year-on-year increase in revenue for the first half of the year, amounting to RMB 1.146 billion, and achieved a profit attributable to shareholders of RMB 103 million, marking a turnaround from losses [1] Group 2 - The establishment of a joint AI research and development company signifies a substantial step in Sihuan Pharmaceutical's strategic layout in the "AI + medical beauty" innovation sector [1] - The company's medical beauty platform, Meiyan Space, has successfully enhanced strategic partnerships with various medical beauty institutions and implemented a marketing strategy upgrade, leading to a significant increase in sales revenue [1] - Sihuan Pharmaceutical plans to distribute an interim cash dividend of HKD 0.0099 per share [1]

Group 1 - The core viewpoint of the article is that Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Pharmaceutical Biotechnology (Beijing) Co., Ltd. to promote the application of artificial intelligence (AI) in the research and development of medical beauty products [1] - The collaboration aims to establish an AI research and development company led by Four Seasons Pharmaceutical, focusing on the exploration of AI-driven new medical beauty product development [1] - This initiative marks a significant step in the strategic layout of the "AI + Medical Beauty" innovation track for the company [1]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" landscape [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven innovations in medical aesthetics [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Strategic Objectives - The collaboration aims to break through raw material bottlenecks and upgrade the medical aesthetics business by utilizing Deep Origin's unique protein design platform to address challenges in the design, optimization, and expression of core injectable materials [1] - The initiative is expected to reduce reliance on imported high-end materials, promoting the upgrade of medical aesthetics products towards "high-end and domestically produced" solutions, thereby strengthening market share and brand influence [1] Group 3: R&D Efficiency and Innovation - The partnership will enhance the efficiency of medical aesthetics R&D processes by integrating deep generative models and high-throughput experimental validation systems, which will shorten the early-stage molecular screening cycle and lower development costs [2] - The establishment of the AI R&D company will focus on creating globally innovative raw materials and products, addressing unmet market needs and injecting momentum into the long-term development of the medical aesthetics business [2]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" innovation track [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven new medical aesthetic product development [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Technological Advancements - The collaboration aims to create a "dry-wet closed-loop" R&D platform that integrates AI design, high-throughput experimental validation, and data feedback iteration, enhancing the value of the medical aesthetics business [2] - The use of advanced generative models and large language models will shorten the early-stage R&D molecular screening cycle, reduce development costs, and improve the success rate of R&D in the medical aesthetics field [2] Group 3: Market Positioning - The focus on high-end medical aesthetic raw material innovation aims to break the dependency on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetic products towards "high-end and domestically produced" [1] - The collaboration is expected to address unmet market needs in the medical aesthetics sector, injecting momentum into the long-term development of Four Seasons' medical aesthetics business and enhancing its core competitiveness and market value [2]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" landscape [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven innovations in medical aesthetics [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will contribute its proprietary protein design automation platform and core technologies [1] Group 2: Strategic Objectives - The collaboration aims to break through raw material bottlenecks and upgrade the medical aesthetics business by utilizing Deep Origin's unique protein design platform to address challenges in the design, optimization, and expression of core injectable materials [1] - The initiative is expected to reduce reliance on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetics products towards "high-end and domestically produced" offerings, thereby strengthening market share and brand influence [1] Group 3: R&D Efficiency and Innovation - The partnership will enhance the efficiency of medical aesthetics R&D processes by integrating deep generative models and high-throughput experimental validation systems, which will shorten the early-stage molecular screening cycle and reduce development costs [2] - The establishment of the AI R&D company will focus on globally pioneering raw materials and product development, addressing unmet market needs and injecting momentum into the long-term growth of Four Seasons' medical aesthetics business [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 四環醫藥與深原質藥聯合成立AI研發公司 探索開發AI驅動的新型醫美產品 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為「本集團」）董 事 會（「董事會」）欣 然 宣 佈，為 推 動 人 工 智 慧 技 術（「AI」）在 醫 療 美 容（「醫 美」）產 品 研 發 領 域 的 深 度 應 用 與 產 業 化 落 地，本 集 團 已 與 深 原 質 藥 生 物 科 技（北 京）有 限 公 司（「深原質藥」）簽 署 框 架 協 議。雙 方 將 聯 合 成 立 由 本 集 團 主 導 的AI研 發 公 司，共 同 探 ...

Core Insights - The company has reported a significant growth in both its medical aesthetics and innovative pharmaceutical businesses, with multiple key products receiving approval for commercialization [1][4][10] - The total revenue for the first half of the year reached approximately 1.146 billion RMB, representing a year-on-year increase of about 20.7%, while the profit attributable to shareholders was approximately 103 million RMB, marking a successful turnaround from losses [2][4] - The company declared an interim cash dividend of 0.99 RMB per share, highlighting its strong return capability since its IPO in 2010, with a total of 33 dividends amounting to approximately 7.5 billion RMB by the end of 2024 [2] Innovative Pharmaceutical Business - The innovative pharmaceutical segment has seen explosive growth, with revenues from innovative drugs and other pharmaceuticals reaching 58.2 million RMB, a year-on-year increase of 96.6%, driven primarily by a surge in sales of diabetes medications [4][6] - The company has optimized its business structure, allowing for efficient conversion of research and development results into commercial success, with R&D expenses decreasing by 21.9% to 153 million RMB [6][4] - Key products such as the anti-tumor drug Pyrocilin and the proton pump inhibitor Annelaz sodium have been approved and are expected to contribute significantly to revenue growth [6][7] Medical Aesthetics Business - The medical aesthetics segment achieved revenues of approximately 580 million RMB, reflecting a year-on-year growth of 81.3%, supported by strategic partnerships and an upgraded marketing strategy [10][11] - The company has launched several self-developed products, making it the first in the industry to offer a comprehensive range of aesthetic solutions, which is expected to drive further revenue growth [10][11] - A robust marketing network has been established, covering over 6,800 medical aesthetic institutions, ensuring rapid product distribution and market penetration [11] Strategic Outlook - The company has demonstrated strong execution capabilities and strategic foresight in both the innovative pharmaceutical and medical aesthetics sectors, with a focus on long-term growth [13] - With a cash reserve of nearly 3.9 billion RMB, the company is well-positioned for continued innovation and market expansion [13] - The market is beginning to recognize the company's intrinsic value, as evidenced by a stock price increase of over 150% within the year, indicating a potential for valuation re-rating [13]

四环医药(00460)发布公告，公司现任执行董事陈燕玲女士将获委任为公司提名委员会委员，自2025年9 月1日起生效。 ...

智通财经APP讯，四环医药(00460)发布公告，公司现任执行董事陈燕玲女士将获委任为公司提名委员会 委员，自2025年9月1日起生效。 该信息由智通财经网提供 ...